Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
Liang ZhangYixin YaoShaojun ZhangYang LiuHui GuoMakhdum AhmedTaylor BellHui ZhangGuangchun HanElizabeth LorenceMaria BadilloShouhao ZhouYuting SunMaria Emilia Di FrancescoNingping FengRandy HaunRenny Shang-Lun LanSamuel G MackintoshXizeng MaoXingzhi SongJianhua ZhangLan V PhamPhilip L LorenziJoseph R MarszalekTimothy P HeffernanGiulio F DraettaPhilip JonesP Andrew FutrealKrystle NomieLinghua WangMichael L WangPublished in: Science translational medicine (2020)
Metabolic reprogramming is linked to cancer cell growth and proliferation, metastasis, and therapeutic resistance in a multitude of cancers. Targeting dysregulated metabolic pathways to overcome resistance, an urgent clinical need in all relapsed/refractory cancers, remains difficult. Through genomic analyses of clinical specimens, we show that metabolic reprogramming toward oxidative phosphorylation (OXPHOS) and glutaminolysis is associated with therapeutic resistance to the Bruton's tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma (MCL), a B cell lymphoma subtype with poor clinical outcomes. Inhibition of OXPHOS with a clinically applicable small molecule, IACS-010759, which targets complex I of the mitochondrial electron transport chain, results in marked growth inhibition in vitro and in vivo in ibrutinib-resistant patient-derived cancer models. This work suggests that targeting metabolic pathways to subvert therapeutic resistance is a clinically viable approach to treat highly refractory malignancies.